by European Public Health Alliance | Apr 20, 2022 | Antimicrobial Resistance | Analysis & Opinion, COVID-19, Digital Health | Analysis & Opinion, Healthy Economic Policy | Analysis & Opinion, Non Communicable Diseases (NCDs), Universal Access and Affordable Medicines | Analysis & Opinion
The European Parliament is undertaking an extremely important task of examining how the European Union has dealt with the response to the ongoing COVID-19 pandemic. We know that its impact on almost every aspect of our lives and livelihoods has been and often...
by European Public Health Alliance | Feb 25, 2022 | COVID-19, The View from EPHA, Universal Access and Affordable Medicines | Analysis & Opinion
Guest article by Tamsin Rose, Senior Fellow for Health at Friends of Europe and former Secretary-General at EPHA COVID-19 was unprecedented but not unpredicted. In 2018, the WHO designated ‘Disease X‘ as representing the knowledge that a serious international epidemic...
by Yannis Natsis | Dec 28, 2021 | Universal Access and Affordable Medicines | Analysis & Opinion
The December 2021 Council Conclusions negotiated under the Slovenian Presidency of the EU and signed off by all 27 EU Health Ministers offer a helpful snapshot of where the pharmaceuticals debate stands today, nearly two years into the COVID-19 pandemic and one year...
by Yannis Natsis | Nov 30, 2021 | #EU4Health, Universal Access and Affordable Medicines | Analysis & Opinion
The EU’s Pharmaceutical Strategy is a roadmap which will accompany policy developments for the years to come. It is important as it offers a rare and concise overview of actions and priorities which guide EU policy action. It is indeed a reference point as much as a...
by Milka Sokolović | Jul 8, 2021 | #EU4Health, The View from EPHA, Universal Access and Affordable Medicines | Analysis & Opinion
The access to medicines debate in Europe is at a critical juncture. With the pandemic, all issues, old and new, suddenly find a place on the agenda. They range from the prices of medicines, the flexibility of regulatory standards, the quality of innovation, all the...
by Yannis Natsis | Jul 8, 2021 | Universal Access and Affordable Medicines | Analysis & Opinion
Undeniably, pharmaceutical companies’ power and influence have grown in the context of the current pandemic. The politicisation of pharmaceuticals is unprecedented. Pharma CEOs pick up the phone and talk directly to EU heads of state and governments. Companies are...
